广州中医药大学学报2026，Vol.43Issue(1)：79-85,7.DOI:10.13359/j.cnki.gzxbtcm.2026.01.012
祛瘀生新方对溃疡性结肠炎患者肠道菌群多样性、肠黏膜屏障指标及中医证候积分的影响
Effects of Quyu Shengxin Formula on Gut Microbiota Diversity,Intestinal Mucosal Barrier Indicators,and TCM Syndrome Scores in Patients with Ulcerative Colitis
摘要
Abstract
Objective To investigate the effects of Quyu Shengxin Formula(composed of Astragali Radix,Pseudostellariae Radix,Atractylodis Macrocephalae Rhizoma,Rehmanniae Radix,Kummerowiae Herba,Euphorbiae Humifusae Herba,Persicae Semen,and Chuanxiong Rhizoma)on gut microbiota diversity,intestinal mucosal barrier indicators,and traditional Chinese medicine(TCM)syndrome scores in patients with ulcerative colitis(UC).Methods A total of 100 UC patients with spleen-stomach qi deficiency syndrome treated at the Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine between November 2022 and October 2024 were randomized into two groups using a random number table method:the conventional group(n=50)and the Quyu Shengxin group(n=50).The conventional group received standard western medicine treatment with Mesalazine Enteric-Coated Tablets combined with Bifidobacterium and Lactobacillus triple viable tablets.The Quyu Shengxin group received Quyu Shengxin Formula in addition to the conventional treatment.Both groups were treated for three treatment courses,with one month as a course.Changes in gut microbiota diversity,intestinal mucosal barrier indicators,and TCM syndrome scores were observed before and after treatment,and clinical efficacy was evaluated.Results(1)Regarding clinical efficacy,after three months of treatment,the total effective rate was 96.00%(48/50)in the Quyu Shengxin group and 82.00%(41/50)in the conventional group.The intergroup comparison(by chi-square test)showed that the Quyu Shengxin group demonstrated significantly superior efficacy compared to the conventional group(P＜0.05).(2)In terms of gut microbiota diversity,after treatment,both groups showed significant increases in Bifidobacterium and Lactobacillus(P＜0.01)and significant decreases in Enterococcus and Enterobacter compared to pre-treatment level(P＜0.01).The Quyu Shengxin group exhibited significantly greater increases in Bifidobacterium and Lactobacillus and greater reductions in Enterococcus and Enterobacter than the conventional group(P＜0.05).(3)For intestinal mucosal barrier indicators,after treatment,both groups showed significant decreases in serum diamine oxidase(DAO),D-lactic acid,and endotoxin(ET)levels(P＜0.01),with the Quyu Shengxin group demonstrating significantly greater reductions than the conventional group(P＜0.05).(4)Regarding TCM syndrome scores,after treatment,both groups exhibited significant reductions in scores for abdominal pain,diarrhea,mucoid bloody stool,and poor appetite(P＜0.01),with the Quyu Shengxin group showing significantly greater reductions than the conventional group(P＜0.05).Conclusion Quyu Shengxin Formula demonstrates remarkable clinical efficacy in treating UC patients with spleen-stomach qi deficiency syndrome.It significantly alleviates symptoms such as mucoid bloody stool and abdominal pain,reduces TCM syndrome scores,enhances gut microbiota diversity,promotes the proliferation of probiotics including Bifidobacterium and Lactobacillus,inhibits the growth of pathogenic bacteria,optimizes the intestinal microecological environment,repairs the damaged intestinal mucosal barrier,and strengthens intestinal defense function.These findings highlight the comprehensive advantages of Quyu Shengxin Formula in regulating gut microbiota,repairing the intestinal mucosa,and improving clinical symptoms of the UC patients.关键词
祛瘀生新方/溃疡性结肠炎/脾胃气虚型/肠道菌群多样性/肠黏膜屏障指标/中医证候积分Key words
Quyu Shengxin Formula/ulcerative colitis(UC)/spleen-stomach qi deficiency syndrome/gut microbiota diversity/intestinal mucosal barrier indicators/TCM syndrome scores分类
医药卫生引用本文复制引用
尹本翻,陈步强,张旗林,梁彪,钱诗维,黄硕,王振宜..祛瘀生新方对溃疡性结肠炎患者肠道菌群多样性、肠黏膜屏障指标及中医证候积分的影响[J].广州中医药大学学报,2026,43(1):79-85,7.基金项目
国家自然科学基金资助项目(编号:82274531) （编号:82274531）
中央财政支持中医药传承创新发展示范试点项目(编号:YC-2023-0122) （编号:YC-2023-0122）
